Literature DB >> 2512330

Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.

I Eichler1, L Joris, Y P Hsu, J Van Wye, R Bram, R Moss.   

Abstract

Antibody opsonins from cystic fibrosis (CF) patients were investigated using nonmucoid and mucoid lipopolysaccharide (LPS) immunotype 1 Pseudomonas aeruginosa as bacterial ligands and PMN phagocytes. CF sera were compared to normal sera, polyvalent PA LPS hyperimmune globulin, and isotype switch variant monoclonal antibodies (MAbs) specific for type 1 PA LPS. Sera from PA-infected CF patients (CF PA+) had elevated levels of PA LPS and alginate IgG antibodies and promoted significantly greater antibody-dependent PMN chemiluminescence responses than sera from uninfected CF patients (CF PA-) or normal human sera (NHS). After adjustment for autologous IgG PA LPS antibody content, however, CF PA+ sera had less antibody-dependent opsonic activity than sera from CF PA- patients (P less than 0.025) or NHS (P less than 0.0025), suggesting qualitative opsonic defects of IgG PA LPS antibodies in CF PA+ sera. Antigen-specific immunoprecipitation of PA LPS antibodies enhanced opsonization by 40% of CF PA+ sera while uniformly reducing that from CF PA- sera (P less than 0.01), indicating LPS-specific nonopsonic antibodies in some CF PA+ sera. Alginate antibodies were not critical opsonins in most uninfected CF patient sera. PA LPS IgG antibodies isolated by immunoaffinity chromatography from NHS, hyperimmune globulin, and CF PA- sources were opsonic and had greater activity at equal antigen-binding concentration than identical antibodies isolated from infected CF patients (P less than 0.01-0.05); the majority of isolates from CF PA+ sera did not promote PMN oxidative responses above nonopsonic baseline. A potential isotypic basis for these findings was supported by differences in PMN responses to PA opsonized with MAbs of identical specificity but differing isotypes. PA LPS-specific IgG antibodies inhibiting PMN oxidative responses in infected patient sera demonstrate antigen-specific immunomodulation of host responses by chronic bacterial parasitism in CF, which may play a role in the pathophysiology of lung disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2512330      PMCID: PMC304057          DOI: 10.1172/JCI114364

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

1.  Selective inhibition of phagocytic activity of rabbit alveolar macrophages by cystic fibrosis serum.

Authors:  B Boxerbaum; A Kagumba; L W Matthews
Journal:  Am Rev Respir Dis       Date:  1973-10

2.  Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides.

Authors:  L S Young
Journal:  J Infect Dis       Date:  1972-09       Impact factor: 5.226

3.  Complement-mediated phagocytosis of Pseudomonas aeruginosa.

Authors:  P K Peterson; Y Kim; D Schmeling; M Lindemann; J Verhoef; P G Quie
Journal:  J Lab Clin Med       Date:  1978-12

4.  Inhibitory effect of cystic fibrosis serum on pseudomonas phagocytosis by rabbit and human alveolar macrophages.

Authors:  M J Thomassen; B Boxerbaum; C A Demko; P J Kuchenbrod; D G Dearborn; R E Wood
Journal:  Pediatr Res       Date:  1979-09       Impact factor: 3.756

5.  Opsonic defect in patients with cystic fibrosis of the pancreas.

Authors:  W D Biggar; B Holmes; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1971-08       Impact factor: 11.205

6.  Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.

Authors:  M Pollack; L S Young
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

7.  Immunologic investigations of mucoid strains of Pseudomonas aeruginosa: comparison of susceptibility to opsonic antibody in mucoid and nonmucoid strains.

Authors:  R S Baltimore; M Mitchell
Journal:  J Infect Dis       Date:  1980-02       Impact factor: 5.226

8.  Optimal conditions for simultaneous purification of mononuclear and polymorphonuclear leucocytes from human blood by the Hypaque-Ficoll method.

Authors:  A Ferrante; Y H Thong
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

9.  Altered antibody isotype in cystic fibrosis: impaired natural antibody response to polysaccharide antigens.

Authors:  R B Moss; Y P Hsu; P H Van Eede; A M Van Leeuwen; N J Lewiston; G De Lange
Journal:  Pediatr Res       Date:  1987-12       Impact factor: 3.756

10.  Use of Pseudomonas aeruginosa lipopolysaccharide immunoadsorbents to prepare high potency, mono-specific antibodies.

Authors:  R B Fick; G P Naegel; H Y Reynolds
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

View more
  12 in total

1.  Avidity of anti-P aeruginosa antibodies during chronic infection in patients with cystic fibrosis.

Authors:  O Ciofu; T D Petersen; P Jensen; N Høiby
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Lymphocytes in cystic fibrosis lung disease: a tale of two immunities.

Authors:  R B Moss
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

Review 3.  Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment.

Authors:  Samuel M Moskowitz; Ronald L Gibson; Eric L Effmann
Journal:  Pediatr Radiol       Date:  2005-05-03

Review 4.  Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management.

Authors:  N Høiby; C Koch
Journal:  Thorax       Date:  1990-11       Impact factor: 9.139

5.  Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects.

Authors:  Allan W Cripps; Keith Peek; Margaret Dunkley; Kevin Vento; Joanne K Marjason; Madonna E McIntyre; Phil Sizer; Duncan Croft; Lis Sedlak-Weinstein
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

6.  Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis.

Authors:  S Renner; R Rath; P Rust; S Lehr; T Frischer; I Elmadfa; I Eichler
Journal:  Thorax       Date:  2001-01       Impact factor: 9.139

7.  Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide.

Authors:  M J Preston; A A Gerçeker; M E Reff; G B Pier
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  Complement activation by polyclonal immunoglobulin G1 and G2 antibodies against Staphylococcus aureus, Haemophilus influenzae type b, and tetanus toxoid.

Authors:  R G Bredius; P C Driedijk; M F Schouten; R S Weening; T A Out
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

9.  Eosinophilic activation in cystic fibrosis.

Authors:  D Y Koller; M Götz; I Eichler; R Urbanek
Journal:  Thorax       Date:  1994-05       Impact factor: 9.139

10.  Anti-Pseudomonas aeruginosa IgG subclass titers in patients with cystic fibrosis: correlations with pulmonary function, neutrophil chemotaxis, and phagocytosis.

Authors:  R G Cowan; G B Winnie
Journal:  J Clin Immunol       Date:  1993-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.